Regulatory Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings Pharmaceutical TechnologyThe EMA's CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.RegulatoryRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaceutical Technology The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Daiichi Sankyo shares slip after delaying annual earnings reportNext: Gene therapy leaders aim to help more Baby KJs with novel regulatory models Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
